NASDAQ:JANX Janux Therapeutics Q1 2026 Earnings Report $14.18 -0.36 (-2.48%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$14.13 -0.05 (-0.32%) As of 05/8/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Janux Therapeutics EPS ResultsActual EPS-$0.39Consensus EPS -$0.52Beat/MissBeat by +$0.13One Year Ago EPSN/AJanux Therapeutics Revenue ResultsActual Revenue$3.73 millionExpected Revenue$4.36 millionBeat/MissMissed by -$624.00 thousandYoY Revenue GrowthN/AJanux Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsJanux Therapeutics' Q2 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Janux Therapeutics Earnings HeadlinesJanux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash ValueMay 4, 2026 | seekingalpha.comJonesTrading Cuts Janux Therapeutics (NASDAQ:JANX) Price Target to $28.00May 1, 2026 | americanbankingnews.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.May 9 at 1:00 AM | Profits Run (Ad)Janux Therapeutics halts early stage cancer program in 'prudent' moveApril 28, 2026 | msn.comJANX stock edges up after hours after discontinuing cancer program in favor of remaining pipelineApril 28, 2026 | msn.comJanux Therapeutics Announces Discontinuation of JANX008 Clinical DevelopmentApril 28, 2026 | finance.yahoo.comSee More Janux Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email. Email Address About Janux TherapeuticsJanux Therapeutics (NASDAQ:JANX) is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration. By activating key pathways of the innate immune response, these candidates aim to recruit and amplify antitumor T-cell activity while minimizing systemic exposure. Janux’s pipeline is advancing through early-stage clinical trials to evaluate safety, tolerability and preliminary signals of efficacy in a variety of solid tumors. Based in San Diego, Janux leverages collaborations with contract research organizations and academic centers to support manufacturing and clinical development. The company’s leadership team comprises experienced immuno-oncology researchers and drug developers with backgrounds in biologics, formulation science and regulatory strategy. Janux continues to build its infrastructure and partnerships to accelerate the translation of its TLR agonists from preclinical research into potential new treatment options for cancer patients. View Janux Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/04 - 05/08Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusWater Infrastructure: Why This Boring Sector Could Get ExcitingAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely Wrong Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
